| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8440877 | European Journal of Cancer | 2016 | 9 Pages |
Abstract
The cumulative risk of SMN after 131I-MIBG therapy for patients with relapsed or refractory neuroblastoma is similar to the greatest published incidence for high-risk neuroblastoma after myeloablative therapy, with no dose-dependent increase. As the number of patients treated and length of follow-up time increase, it will be important to reassess this risk.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Kelly E. Huibregtse, Kieuhoa T. Vo, Steven G. DuBois, Stephanie Fetzko, John Neuhaus, Vandana Batra, John M. Maris, Brian Weiss, Araz Marachelian, Greg A. Yanik, Katherine K. Matthay,